Key result
New daunorubicin analogs show no antitumor benefit against murine leukemia despite lacking toxicity.
Why the study?
New daunorubicin analogs were synthesized and assayed to evaluate their in vivo activity and toxicity against P388 lymphocytic leukemia.
New daunorubicin analogs showed little to no in vivo activity against P388 lymphocytic leukemia but lacked toxicity.
Answers are grounded in this paper and cite their sources.
New daunomycinone glycosides synthesized; leaves open their antibiotic or cytotoxic activity pending biological testing.
Glycosidation of 2,3,6-trideoxy-3-trifluoroacetamido-4-O-trifluoroacetyl-alpha-D-arabino-hexopyranosyl chloride (19) (or the corresponding 4-p-nitrobenzoate, 20) with daunomycinone under Koenigs-Knorr conditions afforded, after separation of the anomers and removal of the protecting groups, the individual target glycosides 8 (alpha anomer; major product) and 9 (beta; minor) in acceptable yields. In contrast, the title diamino sugar, suitably protected with N-trifluoroacetyl and O-acetyl (or O-p-nitrobenzoyl) groups, underwent stereospecific coupling to the anthracycline aglycon by the glycal procedure to give, after deprotection, the alpha glycoside 12. All three analogs were assayed in vivo against P388 lymphocytic leukemia. They showed little (T/C 125 for 8; T/C 115 for 9) or no (compound 12) activity, but were essentially devoid of toxicity at the dose-levels tested.
No takes yet. Share an insight, caveat, or question.
Fuchs et al. (1979) studied P388 lymphocytic leukemia. Daunorubicin analogs (compounds 8, 9, and 12) vs. Daunorubicin, adriamycin, and untreated controls was evaluated on Ratio of median survival time expressed as percent of untreated controls (T/C %). The new daunorubicin analogs 8, 9, and 12 showed little to no antitumor activity against murine P388 lymphocytic leukemia but were devoid of toxicity at the tested doses.
Synapse has enriched 10 related papers. Consider them for comparative context: